Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WJMSCs in Ischemic Cardiomyopathy
NCT02368587Phase 2Unknown
- Start
- Jan 2020
- Primary completion
- Jan 2021
- Modality
- Stem Cell Therapies
01
Overview
Phase 2, randomised, double-blind trial of wharton's jelly mesenchymal stromal cells in ischemic cardiomyopathy (ICM) (4 arms). Primary endpoint: Incidence of adverse events at 12 months. Status: unknown.
02
Drugs
wharton's jelly mesenchymal stromal cells
03
Conditions
ischemic cardiomyopathy (ICM)
Beyond the preview
Go deeper on NCT02368587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02368587.